GDTC Stock News & Catalysts – CytoMed Therapeutics

FEATURED

CytoMed Therapeutics Limited Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

SINGAPORE, Oct. 09, 2026 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (the "Company") (NASDAQ:GDTC), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary

Summary

Oct 9, 2026, 4:30 PM ·Globe Newswire

RECENT

CytoMed Therapeutics Refutes Misleading Claims and Reaffirms Clinical Progress

SINGAPORE, Jan. 28, 2026 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or the "Company"), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary

Jan 28, 2026, 10:00 AM ·Globe Newswire

CytoMed Therapeutics' new year update and seeks shareholders' feedback on proposal to improve shareholder value for their patient capital

SINGAPORE, Jan. 13, 2026 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or the "Company"), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary

Jan 13, 2026, 8:00 AM ·Globe Newswire

CytoMed Therapeutics Announces Novel First-In-Human Clinical Trial Collaborations with Renowned and Prestigious Hospital Partner to Advance Its Off-The-Shelf Donor-Derived Gamma Delta T Cells Allogeneic Technology to Treat Cancers in Malaysia

SINGAPORE, Dec. 08, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or the "Company"), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary

Dec 8, 2025, 8:00 AM ·Globe Newswire

CytoMed Therapeutics Completes Acquisition of T Cell Technology from UK to Treat Cancers in China and India

SINGAPORE, Nov. 18, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "Company"), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary novel

Nov 18, 2025, 8:00 AM ·Globe Newswire

CytoMed Therapeutics Secures Non-Dilutive Investment for Subsidiary LongevityBank from ICH Capital and Updates on New China Strategy

SINGAPORE, Nov. 06, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "Company"), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary

Nov 6, 2025, 8:00 AM ·Globe Newswire

CytoMed Therapeutics' Chairman Increases Effective Holdings to 21.95%

SINGAPORE, Oct. 22, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "Company"), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary

Oct 22, 2025, 8:00 AM ·Globe Newswire

Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge

Equity Insider News Commentary Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Oct. 15, 2025 /PRNewswire/ -- Eight new oncology approvals between July and September 2025 marked a pivotal quarter for cancer

Oct 15, 2025, 8:45 AM ·PRNewswire

CytoMed makes cash bid for potential acquisition of TC BioPharm Limited's relevant assets

SINGAPORE, Oct. 14, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "Company"), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary

Oct 14, 2025, 8:00 AM ·Globe Newswire

CytoMed Therapeutics Announces Publication of Collaborative Research with The University of Texas, MD Anderson Cancer Center, Demonstrating the Potential of Allogeneic γδ T Cells in Acute Myeloid Leukemia

SINGAPORE, Oct. 02, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "Company"), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary

Oct 2, 2025, 7:00 AM ·Globe Newswire

Update on recent acquisition - CytoMed Therapeutics expands into auto-immune diseases building on its recent cord blood bank acquisition

SINGAPORE, Aug. 28, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "Company"), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary

Aug 28, 2025, 9:00 AM ·Globe Newswire

CytoMed Therapeutics Limited Announces At-the-Market (ATM) Offering Program

SINGAPORE, Aug. 18, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "Company"), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary

Aug 18, 2025, 9:00 PM ·Globe Newswire

Update On Clinical Trial Milestone - CytoMed Therapeutics Achieves Completion of Dose Level 1 of its ANGELICA TRIAL, and Proceeding to Dose Level 2 in Patients with Advanced Solid Tumors or Haematological Malignancies

SINGAPORE, July 21, 2025 (GLOBE NEWSWIRE) -- Further to our announcement filed on Form 6-K on November 20, 2024, CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "Company"), a Singapore-based clinical stage

Jul 21, 2025, 10:01 AM ·Globe Newswire

CytoMed Therapeutics Reports Full Year Ended December 31, 2024 Financial Results and Provides Clinical and Corporate Updates

SINGAPORE, April 28, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or the "Company"), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary

Apr 28, 2025, 4:05 PM ·Globe Newswire

CytoMed Therapeutics announces Chairman's Letter to the Company's shareholders

SINGAPORE, Feb. 06, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or the "Company") today released a letter to shareholders from the Chairman of the Company's Board of Directors (the

Feb 6, 2025, 7:20 AM ·Globe Newswire

CytoMed Therapeutics Limited GDTC · News